Enhanced recovery after surgery compliance and postoperative recovery in elderly colorectal cancer patients: a propensity score matched cohort study.
[BACKGROUND] Enhanced Recovery After Surgery (ERAS) pathways are standard in colorectal surgery, but evidence in elderly patients is limited.
- p-value p<0.01
- p-value p=0.043
APA
Wang J, Wang Q, et al. (2026). Enhanced recovery after surgery compliance and postoperative recovery in elderly colorectal cancer patients: a propensity score matched cohort study.. Frontiers in oncology, 16, 1760602. https://doi.org/10.3389/fonc.2026.1760602
MLA
Wang J, et al.. "Enhanced recovery after surgery compliance and postoperative recovery in elderly colorectal cancer patients: a propensity score matched cohort study.." Frontiers in oncology, vol. 16, 2026, pp. 1760602.
PMID
42038370
Abstract
[BACKGROUND] Enhanced Recovery After Surgery (ERAS) pathways are standard in colorectal surgery, but evidence in elderly patients is limited. This study evaluated the impact of ERAS adherence on outcomes after curative colorectal cancer (CRC) resection in patients ≥65 years.
[METHODS] A single-centre, retrospective cohort of elderly CRC patients undergoing elective resection (2021-2024) was analysed. Adherence to 15 ERAS items was assessed; ≥80% (≥12 items) defined high compliance. Propensity score matching (1:1) balanced baseline characteristics. Primary endpoints were postoperative length of stay (LOS) and 30-day major morbidity; secondary endpoints included recovery milestones and 12-month functional outcomes.
[RESULTS] Of 256 screened patients, 150 were matched (75 per group). High compliance was associated with shorter LOS, higher discharge within 10 days (73.3% vs 40.0%; p<0.01), and fewer major complications (14.0% vs 22.0%; p=0.043). Recovery milestones occurred earlier in the high-compliance group: ambulation (22.6 vs 26.1 h), bowel recovery (32.1 vs 36.0 h), and oral intake (30.5 vs 34.8 h). At 12 months, more patients resumed a normal diet without obstructive symptoms (92.9% vs 81.5%; p=0.021).
[CONCLUSIONS] In elderly CRC patients, high ERAS compliance was linked to shorter LOS, reduced morbidity, faster recovery, and sustained dietary benefit. Improving adherence may optimise outcomes, warranting validation in multicentre studies.
[METHODS] A single-centre, retrospective cohort of elderly CRC patients undergoing elective resection (2021-2024) was analysed. Adherence to 15 ERAS items was assessed; ≥80% (≥12 items) defined high compliance. Propensity score matching (1:1) balanced baseline characteristics. Primary endpoints were postoperative length of stay (LOS) and 30-day major morbidity; secondary endpoints included recovery milestones and 12-month functional outcomes.
[RESULTS] Of 256 screened patients, 150 were matched (75 per group). High compliance was associated with shorter LOS, higher discharge within 10 days (73.3% vs 40.0%; p<0.01), and fewer major complications (14.0% vs 22.0%; p=0.043). Recovery milestones occurred earlier in the high-compliance group: ambulation (22.6 vs 26.1 h), bowel recovery (32.1 vs 36.0 h), and oral intake (30.5 vs 34.8 h). At 12 months, more patients resumed a normal diet without obstructive symptoms (92.9% vs 81.5%; p=0.021).
[CONCLUSIONS] In elderly CRC patients, high ERAS compliance was linked to shorter LOS, reduced morbidity, faster recovery, and sustained dietary benefit. Improving adherence may optimise outcomes, warranting validation in multicentre studies.
같은 제1저자의 인용 많은 논문 (5)
- "A diamond-shaped" penoplasty technique with or without concurrent suprapubic liposuction for adult-acquired buried penis: clinical outcomes and patient satisfaction rates.
- A Systematic Review of Patient-Reported Outcomes for Cosmetic Indications of Botulinum Toxin Treatment.
- Impact of diagnosis-related group systems on inpatient expenditures and medical quality for children with leukemia: evidence from real-world data.
- A preliminary study to evaluate efficacy and safety of Lugol's solution following radioiodine for remnant ablation in differentiated thyroid cancer.
- Lentinan inhibits breast cancer cell growth through the dual downregulation of tumor-promoting effectors CD133 and SCGB2A2.